Navigation Links
Sigma-Aldrich Licenses From NeuroSurvival Technologies a Leading Marker for Molecular Imaging of Apoptosis in Vivo
Date:2/26/2008

The marker, Apo-TRACE(TM), offers a breakthrough in advancing apoptosis-related research in a range of fields in biology and medicine

ST. LOUIS, Feb. 26 /PRNewswire-FirstCall/ -- Sigma-Aldrich(TM) (Nasdaq: SIAL) and NeuroSurvival Technologies Ltd. (NST) announced today that they have signed a licensing agreement for a leading marker, developed by NST, for molecular imaging of apoptosis in vitro and in vivo in animals. The marker, developed by NST, will be manufactured and marketed by Sigma-Aldrich under the commercial name Apo-TRACE(TM) (http://www.sigma.com/apotrace). Apo-TRACE(TM) is a member of a family of proprietary small molecules developed by NST that target apoptosis. Another molecule of the family, ApoSense(TM)-PET, is in clinical trials for imaging apoptosis in vivo in humans with PET (positron emitting tomography) and is not part of this agreement.

Apoptosis (programmed cell death) is a fundamental biological process of cell "suicide", inherent in every cell in body, and its discovery is regarded as one of the major recent revolutions in biology and medicine. Apoptosis has an important role in almost any medical disorder, and its control may hold the promise for substantial advances in medical care for a wide array of medical disorders, ranging from cancer, myocardial infarction and cerebral stroke, to neurodegenerative disorders such as Alzheimer's disease.

Respectively, extensive scientific work is continuously being performed in the field of apoptosis worldwide, involving thousands of research groups, and generating over 17,000* peer-reviewed scientific papers in 2006 alone. Apo-TRACE is a unique and novel solution to the need of researchers for imaging of apoptosis in vivo, in the living organism. As such, it may substantially contribute to advancing preclinical research in variety of fields. Upon a simple intravenous administration, Apo-TRACE selectively targets cells undergoing apoptosis from the early stages of the death process, and, through its fluorescent properties, marks the apoptotic cells, thus enabling easy and accurate detection in vivo of this important cell death process. Thus, by substantially facilitating apoptosis research in vivo, Apo-TRACE offers a breakthrough in advancing apoptosis related research in a range of fields in biology and medicine. Apo-TRACE is available for purchase from Sigma-Aldrich as of January 2008. Once the ApoSense(TM)-PET molecule also becomes commercially available from NST, apoptosis research in vivo will continue into the clinic and become a valuable biomarker for development and testing of new therapeutic agents.

* Based on PubMed database search.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

About NST: NST NeuroSurvival Technologies is a clinical stage molecular imaging and drug development company, focused on the introduction of novel agents based on the identification and targeting of cells undergoing apoptosis (programmed cell death). NST has developed the ApoSense(TM) technology -- A set of proprietary compounds with demonstrated ability to identify, bind and accumulate within apoptotic (dying) cells in vivo. This technology addresses a huge market of unmet research and clinical need across a range of molecular imaging and therapeutic applications. ApoSense(TM)-PET, NST's lead compound for clinical molecular imaging of apoptosis in vivo, using the PET modality, is currently in phase II clinical studies.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.

Apo-TRACE is a trademark of Sigma-Aldrich

ApoSense is a trademark of NST NeuroSurvival Technologies Ltd.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sigma-Aldrich Announces mirPremier(TM) microRNA Isolation Kit for miRNA Purification
2. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
3. EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
4. Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses
5. Researchers propose consumers buy yearly drug licenses as new way to pay for prescriptions
6. DuPont Licenses Breakthrough Automotive Coating Technology to German Paint Maker
7. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
8. Cyberonics Licenses Obesity-Related Patents
9. SuperArray Bioscience Corporation Licenses RNA Interference Patent From The Carnegie Institution
10. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
11. HealthTek Software Solutions Licenses First DataBanks OrderView Med Knowledge Base(TM) to Streamline Medication Selection, Management and Reconciliation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... Santa Clara, CA (PRWEB) , ... June 28, 2017 , ... ... is hosting a free AFM Luncheon for all SEMICONWest attendees and Park ... The luncheon will feature talks from Dr. Sang-il Park, Chairman & CEO of Park ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
(Date:6/27/2017)... ... June 27, 2017 , ... Salucro, the cloud-based payment platform ... industry’s hospitals and provider groups, has announced that it will now offer Parasail’s ... is a San Francisco health-finance startup that has launched a series of tech-based ...
(Date:6/27/2017)... ... June 27, 2017 , ... Two residents from the Gardant-managed assisted living ... designed to encourage lawmakers to protect Medicaid funding. , The video, which was ... highlights the story of Chuck and Cathy Schwarz, a couple who is still able ...
(Date:6/27/2017)... ... 2017 , ... Dr. Richard Amato, a respected periodontist in Monroe, ... Dental Implant Center of Connecticut. As part of the renovation, the cutting-edge practice added ... intended to improve patient comfort while making it possible for Dr. Amato to provide ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... Calif. , June 9, 2017 AirXpanders, ... company focused on the design, manufacture, sale and distribution ... market on the progress of its commercial roll-out in ... now available in more than one hundred (100) medical ... AeroForm offers a needle-free alternative for women ...
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
(Date:6/8/2017)... , June 8, 2017  StatLab ... leading developer and manufacturer of diagnostic supplies ... today that Cressey & Company LP ("Cressey ... has completed a growth-focused investment in the ... majority ownership position from selling shareholder, Prairie ...
Breaking Medicine Technology: